Compare Toyota Motor Corp (TM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toyota Motor Corp vs Twist Bioscience Corp — how do they compare? Toyota Motor Corp trades at $193.77 (market cap $228.43B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Toyota Motor Corp is far larger — about 27.1× Twist Bioscience Corp's market cap, and Toyota Motor Corp pays a 3.27% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TM | TWST | |
|---|---|---|
Market Cap | $228.43B | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $248.29 | $153.10 |
52-Week Low | $166.50 | $24.16 |
Enterprise Value | $427.29B | $8.35B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toyota Motor (TM) trades at $191.45, down 2.87% amid bearish technical signals, though fundamentals remain strong with attractive valuation metrics including a P/E of 8.51 and P/S of 0.74. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $7.57 exceeding estimates by 62%. Recent news highlights strong demand for hybrid models like the RAV4 and strategic partnerships, though tariff threats and a global recall present headwinds.
TM offers value with solid profitability and growth, but faces near-term technical pressure and geopolitical risks. The stock's undervaluation relative to DCF estimates around $342 presents opportunity, yet investors must weigh competitive pressures and macroeconomic uncertainties against the company's operational strength and market leadership in hybrid technology.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
